STOCK TITAN

Enochian Biosciences Inc - ENOB STOCK NEWS

Welcome to our dedicated news page for Enochian Biosciences (Ticker: ENOB), a resource for investors and traders seeking the latest updates and insights on Enochian Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Enochian Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Enochian Biosciences's position in the market.

Rhea-AI Summary
GEDi Cube and Renovaro Biosciences have signed a definitive agreement to combine, with GEDi Cube becoming a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition. The combined company aims to accelerate precision medicine for longevity through AI and biotechnology platforms. GEDi Cube's AI technology will enhance the development of treatments and power the discovery of new therapeutic approaches. Commercial diagnostic products are projected to be available in 2024. Renovaro expects to begin human Phase 1/2 clinical trials for pancreatic cancer and other solid tumors by the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.37%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.26%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.11%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Enochian Biosciences Inc

Nasdaq:ENOB

ENOB Rankings

ENOB Stock Data

44.59M
27.81M
59.52%
5.72%
2.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Los Angeles

About ENOB

enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the company’s lead candidate eno-1001 (pre-ind) is a potentially sterilizing cure for hiv/aids. eno-2001 is an hiv vaccine in preclinical stage, and its additional compounds eno-4001 (phase three asset), eno-4002, eno-5001, and eno-3001 are in discovery stages for prevention relapse in colon cancer patients. enochian biosciences is headquartered in los angeles, california.